Phase 1 N=17 Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
Urticaria
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Part A — 4; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Advanced Solid Tumors · Lymphoma
Primary: Cmax: Maximum Observed Plasma Concentration of Alisertib — 1338.6; 1354.5 nM
Phase 1 N=12 Proellex® Pharmacokinetic Bridging Study II
Healthy
Primary: Cmax of Proellex — 405.5; 426.7; 824.2 ng/mL
N/A N=82 Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Meningococcal Disease · Pregnancy · Infections, Meningococcal
Primary: Percentage of Live Births Reported With Major Congenital Malformations (MCM) on Exposure to Menveo Within 28 Days Prior to Conception — 0.0; 84.6; 15.4 Percentage of…
N/A N=24 Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia
Insomnia
Primary: Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months) — 28.95; 38.91 minutes
N/A N=126 A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Relapses in Participants — 20; 22 Participants — p=0.80
Phase 4 N=23 Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
Type 2 Diabetes
Primary: HbA1C — 8.3; 7.7 mmol/mol
Phase 1 N=11 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Renal Cell Carcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase — 3 Participants
N/A N=176 Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults
Lip Enhancement
Primary: Percentage of Participants With a ≥1-point Increase (Improvement) on the Evaluating Investigator's (EI's) Assessed 5-point Lip Fullness Scale (LFS) — 0; 84.7 percentage…
Phase 4 N=196 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
Gout
Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298
Phase 1 N=55 A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Renal Cell Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1 Participants
Phase 1 N=24 A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
N/A N=63 Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures
Proximal Humeral Fractures
Primary: Shoulder Flexion — 150; 146 Degrees
Phase 1 N=37 A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
Axial Spondyloarthritis (AxSpA) · Non-radiographic Evidence-AxSpA · Ankylosing Spondylitis
Primary: The Plasma Concentration of Certolizumab Pegol (CZP) in the Infant(s) at Birth — NA µg/mL
Phase 3 N=364 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
Cervical Cancer
Primary: Overall Survival — 21.9; 19.5 months — p=0.125